17 Capital Partners LLC Buys 650 Shares of Neurocrine Biosciences, Inc. $NBIX

17 Capital Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 22.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,565 shares of the company’s stock after purchasing an additional 650 shares during the quarter. 17 Capital Partners LLC’s holdings in Neurocrine Biosciences were worth $448,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in NBIX. Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. WPG Advisers LLC bought a new stake in Neurocrine Biosciences during the 1st quarter worth $32,000. SVB Wealth LLC acquired a new position in Neurocrine Biosciences in the 1st quarter worth about $35,000. True Wealth Design LLC raised its position in Neurocrine Biosciences by 1,215.4% in the second quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after purchasing an additional 316 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in Neurocrine Biosciences by 6,285.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 447 shares of the company’s stock valued at $49,000 after purchasing an additional 440 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at approximately $19,933,581.79. This trade represents a 0.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William H. Rastetter sold 18,000 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the sale, the director owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This trade represents a 30.84% decrease in their position. The SEC filing for this sale provides additional information. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Down 0.4%

NBIX stock opened at $138.06 on Thursday. The company’s fifty day simple moving average is $142.46 and its 200 day simple moving average is $133.53. Neurocrine Biosciences, Inc. has a 12-month low of $84.23 and a 12-month high of $157.67. The firm has a market cap of $13.77 billion, a price-to-earnings ratio of 33.03, a PEG ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 28th. The company reported $2.17 EPS for the quarter, beating the consensus estimate of $1.58 by $0.59. The company had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.81 EPS. Research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Canaccord Genuity Group boosted their price target on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Finally, Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $170.53.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.